Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Critical Illness, Deep Venous Thrombosis
Interventions: LMWH (Fragmin, dalteparin), Unfractionated Heparin; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 3,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more

Conditions: Healthy
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Participants
Interventions: BMS-986322, BMS-986322 Placebo, famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Beta-hydroxybutyrate, Normal Saline; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Macular Edema
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more

Conditions: Pelvic Pain Associated With Refractory Endometriosis
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Multiple Organ Failure
Interventions: CoQ10, Placebo; Dietary Supplement
Lead sponsor: American Burn Association; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Weight Management
Interventions: ASC30, Placebo; Drug · Other
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Post Operative Pain
Interventions: Lidocaine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg); Drug
Lead sponsor: PhenoNet, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more

Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine; Biological · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 30
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more

Conditions: Heart Failure
Interventions: Glial growth factor 2/ Neuregulin 1β3, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia • Nashville, Tennessee

Conditions: Healthy
Interventions: Placebo Administration first, Low Caffeine Administration first (1mg/kg body weight), High Caffeine Administration first (2mg/kg body weight); Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 8 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Stroke, Ischemic Stroke, Stroke
Interventions: Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection; Drug · Other
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more

Conditions: Alzheimer's Disease
Interventions: PRX-03140, Donepezil, Placebo; Drug
Lead sponsor: Epix Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • National City, California + 28 more

Conditions: Cardiovascular Diseases, Heart Diseases, Obesity
Interventions: Sibutramine, Behavioral Smoking Cessation Program; Drug · Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pulmonary Artery Hypertension
Interventions: Metformin, Placebo, mHealth Intervention, Usual Care; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Nashvile, Tennessee

Conditions: Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
Interventions: NGM120 Q4W, NGM120 Q8W, Placebo given; Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Santa Rosa, California • Margate, Florida + 9 more

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertriglyceridemia
Interventions: REGN1500, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Suicide, Attempted
Interventions: Ketamine Hydrochloride, Saline, CAMS Therapy; Drug · Behavioral
Lead sponsor: Tatiana Falcone, MD; Other
Eligibility: 14 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Metformin, Insulin, Placebo, Linagliptin, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more

Conditions: HIV-1-infection
Interventions: Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 51
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more

Conditions: Treatment Resistant Depression
Interventions: Placebo, CX157 (TriRima); Drug
Lead sponsor: CeNeRx BioPharma Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 30
States / cities: Escondido, California • National City, California • Oceanside, California + 25 more

Search by objective public record fields.

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Brain Ketone Metabolism in Type 1 Diabetes

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

Systemic Lidocaine Infusion for Pain Control in Ventral Hernia

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Gender Difference in Response to Caffeine in Children and Adolescents

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Intra Uterine Device Insertion in Nulliparous Women

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Ketamine Treatment of Youth Suicide Attempters

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression